4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9 Puritas >98.5% (HPLC) Lenvatinib Mesylate Intermedia Factory

Description:

Nomen: 4-Chloro-7-Methoxyquinoline-6-Carboxamide

CAS: 417721-36-9

Puritas: >98.5% (HPLC)

Aspectus: Off-White ad lux Yellow pulveris

Medium de Lenvatinib Mesylate CAS 857890-39-2

High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com

Mitte ad nos inscriptio

Product Detail

Product Tags

Descriptio:

Ruifu Chemical Supple Lenvatinib Mesylate media cum puritate
Lenvatinib Mesylate CAS 857890-39-2
4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9
Desquinolinyl Lenvatinib;1-(2-Chloro-4-Hydroxyphenyl) -3-Cyclopropylurea CAS 796848-79-8
Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylatus CAS 205448-65-3
Methyl 4-Amino-2-Methoxybenzoate CAS 27492-84-8
5-(Methoxymethylene)-2,2-Dimethyl-1,3-Dioxane-4,6-Dione CAS 15568-85-1
4-Amino-3-Chlorophenol CAS 17609-80-2
4-Amino-3-Chlorophenol Hydrochloride CAS 52671-64-4
Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylatus CAS 205448-66-4

Chemical Properties:

Nomen chemicum	4-Chloro-7-Methoxyquinoline-6-Carboxamide
Synonyma	4-Chloro-7-Methoxy-6-Quinolinecarboxamide;Lenvatinib immunditia 12;Lenvatinib immunditia B;Lenvatinib immunditia LFS-B
CAS Number	417721-36-9
CATTUS Number	RF-PI1971
Stock Status	In Stock, Productio Capacitas 50MT/Annus
Formulae hypotheticae	C11H9ClN2O2
M. Pondus	236.65
Liquescens punctum	>205℃ (dec.)
Density	1.380±0.060 g/cm3
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Aspectus	Off-White ad lux Yellow pulveris
Puritas / Analysis Methodus	>98.5% (HPLC)
Damnum in Siccatio	<0.50%
Residere in Ignition	<0.50%
Totalis immunditias	<1.50%
Proton NMR Spectrum	Conformat ut Structure
Test Standard	Enterprise Standard
Consuetudinem	Medium de Mesylate Lenvatinib (CAS: 857890-39-2)

Sarcina & Repono:

sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris

Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine et humore

commoda:

FAQ:

Applicatio:

4-Chloro-7-Methoxyquinoline-6-Carboxamide (CAS: 417721-36-9) maxime adhibetur ut media mesylate Lenvatinib (CAS: 857890-39-2).Eisai Inc., lenvatinib mesylata enucleata est factor incrementi endothelialis vascularis receptoris (VEGF) inhibitoris qui habet actionem contra VEGF subtyporum 1, 2, et 3, et ab FDA in 2015 probatus est ad curationem cancri thyroideae differentiatae, quae est vel localiter. recurrentes, metastaticae, progressivae vel non respondenti curationi radioactivae iodi.Mense Maio 2016, FDA medicamentum cum everolimo coniunctionis therapiae approbavit ad tractationem carcinomatis renalis promoventis.Quia VEGF (ac receptores fibroblast incrementi factor, ut FGFRs noti) partes agere putantur in viis cardiovascularibus significationis, VEGF2R et FGFR inhibitionis putantur mechanismi post latus primum effectum mesylati lenvatinib, quod est hypertension.